Product Portfolio Review

A UK pharmaceutical company with a diverse portfolio of unpromoted brands, wanted to better understand the potential to improve the performance of 6 brands in their portfolio, worth approximately £10m/yr.

With limited focus on the brands for several years, and internal resources focused on other portfolio needs, the company needed a complete external review to determine the best next steps.

Over six weeks, CHASE carried out a detailed analysis for the company including;

• Analysis of the relevant UK sales data and formulary statuses for the brands and competition
• Reviews of the commercial agreements in place with retail pharmacy, dispensing doctors, primary care and hospitals
• Assessments of the national, regional and local guidelines and guidance status of the brands
• Identification and assessment of new clinical data for the brands and competition

The external review identified growth opportunities for four of the brands

• Two brands required targeted customer promotion
• Retail pharmacy rebates for one brand were too high, with a potential upside of ~£100k/yr
• Hospital pharmacy engagement was required for one brand, where use vs. the main competitor did not reflect the brand’s 1st line formulary position
• CHASE is now working with the client to renew promotion of one of the brands reviewed